Orphan Drug Designation Services for EU and US Rare Disease Programs.
Support for rare disease sponsors.
Orphan drug designation can open the door to meaningful development incentives for rare disease products, including scientific support, fee advantages, and post-approval market exclusivity in key markets.
Arriello supports biotech and pharma sponsors from eligibility assessment and submission strategy through agency interactions, annual reporting, and broader rare-disease regulatory planning across the EU, US, and related UK pathways.
Table of Contents:
What is orphan drug designation?
Orphan drug designation is a regulatory status for medicines intended to diagnose, prevent, or treat rare diseases or conditions.
It exists to encourage development in areas where patient populations are small, unmet need is high, and traditional commercial incentives may be limited.
For sponsors, it can create meaningful advantages during development and after approval, depending on the market and the product.
For rare disease innovators, orphan designation is often more than a procedural step.
It can become an important part of the overall regulatory and investment story, helping define the product’s value proposition, support engagement with regulators, and create a clearer route toward market access.
Who may qualify for orphan designation?
Eligibility requirements differ between the EU and the US, so it is important to assess qualification against the relevant regional framework early in development. A well-prepared application needs more than a broad rare-disease claim. It also needs clear prevalence or population justification, a sound regulatory argument, and a strong presentation of the product’s relevance in the target condition.
EU criteria.
In the European Union, the product must be intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition. The condition must affect no more than 5 in 10,000 people in the EU, or the expected return must be insufficient to justify development. If satisfactory methods already exist, the product must also show significant benefit.
US criteria.
In the United States, orphan designation generally applies to drugs and biologics intended for diseases or conditions affecting fewer than 200,000 people in the US, or where there is no reasonable expectation that development costs can be recovered from US sales within seven years after approval.
An early regulatory review can help confirm whether your product appears suitable for orphan designation and what supporting evidence will be needed for a stronger submission.
Why pursue orphan drug designation?
Orphan drug designation can offer both practical and strategic advantages. Some benefits are formal regulatory incentives, while others come from stronger engagement opportunities and a clearer development pathway for rare disease products.
Key benefits in the EU.
In the EU, orphan designation can provide access to protocol assistance, fee reductions, and eligibility for centralised authorisation. Once approved, the product may also benefit from ten years of market exclusivity for the designated indication. Additional advantages may apply for certain sponsor types, including SMEs.
Key benefits in the US.
In the US, orphan designation may provide tax credits for qualified clinical testing, exemption from certain user fees, and the potential for seven years of orphan exclusivity following approval. The orphan framework can also sit alongside other rare-disease support mechanisms, including grants and other expedited development considerations where applicable.
Why it matters strategically.
For many sponsors, the value of orphan designation extends beyond the listed incentives. It can help shape development planning, support more focused agency dialogue, strengthen investor and partner confidence, and demonstrate commitment to addressing areas of serious unmet patient need.
How Arriello supports orphan drug designation.
Arriello supports orphan designation as part of a broader rare-disease regulatory strategy. Our role can begin with eligibility assessment and continue through submission, validation, agency interaction, annual reporting, and connected planning for later milestones.
Eligibility review and gap analysis.
We can review your current product information and supporting documentation, identify potential gaps, and assess whether the product appears suitable for an orphan designation submission in the EU, the US, or both. This early step helps reduce avoidable delays and improves submission readiness.
Application strategy and preparation.
Arriello can support the full preparation of an orphan designation application, whether from scratch or through targeted review of existing materials. Support can include drafting the application, strengthening the regulatory narrative, preparing a slide deck for a pre-submission meeting where useful, running rehearsal sessions, and helping position the submission for smoother review.
Representation and agency interactions.
Where needed, Arriello can act as the EU legal representative for orphan-related activities and support the practical steps involved in submission and review. We can also assist with portal set-up, validation and evaluation support, meeting preparation, and interactions with authorities during the review process.
Post-designation support.
Our support does not stop at submission. We can help with annual report requirements, orphan-status maintenance considerations at the time of marketing authorisation, and the wider planning needed as the product moves closer to approval. In the EU, post-designation activities, including annual reports, are handled through EMA systems and require ongoing sponsor attention.
Orphan designation as part of a wider rare-disease roadmap.
For many products, orphan designation is only one part of the overall regulatory pathway. The strongest outcomes usually come from connecting orphan planning with the wider development, submission, and access strategy from an early stage.
Arriello can support the related activities that often sit alongside orphan designation, including SME applications, protocol assistance and scientific advice, paediatric investigation plan strategy and management, EU PRIME support, US Breakthrough Therapy planning, UK regulatory options such as PIM, EAMS, ILAP, and UK scientific advice, as well as expanded access and post-trial access planning. We also support market authorisation preparation and submission across the EU, US, and UK.
Why Arriello for ODD?
Arriello combines strategic regulatory science, pharmacovigilance, and quality and compliance support across the product lifecycle. That integrated model is especially valuable for rare disease sponsors, where orphan strategy often needs to connect with clinical development, submission planning, safety oversight, and long-term regulatory maintenance.
Our team brings broad experience across rare-disease and specialty product development, including over 20 years of strategic consulting for EU and US SME and biotech companies, more than 40 scientific advice and agency meetings, over 20 PIP strategies, more than 80 expanded access submissions globally, over 2,000 MAA submissions, and 20+ orphan drug designation submissions with more currently in progress. Arriello also supports sponsors with SME status applications and associated regulatory advantages where relevant.
Sponsors choose Arriello because we combine deep scientific expertise, practical regulatory execution, open communication, and flexible support tailored to the stage and complexity of each program. Rare disease SMEs manage these projects with a focus on clear advice, realistic planning, and hands-on delivery.
Meet some of the regulatory team behind our orphan drug designation support.
Early-phase global regulatory affairs, INDs, NDAs, EAPs, pathway strategy, rare/complex development support.
Senior regulatory strategy and market access expertise, extensive EU submission leadership, dossier and approval process depth.
Experience spanning SME, scientific advice, PIP, ODD, PRIME, and broader early development strategy.
Multi-market submission experience including ODD, PIP, clinical trials, dossier preparation, and regulator communication.
FAQ:
Is orphan drug designation the same as marketing approval?
Does orphan designation offer the same benefits in every region?
Do sponsors need to maintain orphan-related activities after designation?
When should a company start thinking about orphan strategy?
Can Arriello help with more than the designation application itself?
Need support with orphan drug designation?
Whether you are assessing eligibility, preparing your first submission, or connecting orphan strategy to a broader EU and US rare-disease roadmap, Arriello can help you move forward with clarity and confidence. Speak with our regulatory team to discuss your product, your target regions, and the next steps for your program.